BRIDGEWATER, NJ--(MARKET WIRE)--Aug 9, 2007 -- Sapphire Therapeutics, Inc., a private biopharmaceutical company that develops compounds acting within the ghrelin pathway as treatments for metabolic, oncologic, and gastrointestinal diseases, today announced two management promotions and a new appointment that reinforce the company’s team of pharmaceutical development experts who are advancing development of the company’s growing therapeutic pipeline.
